The convergence of artificial intelligence (AI) and blockchain is transforming the Fintech sector by offering innovative solutions in security, regulatory compliance, and operational transparency. This systematic mapping study analyzed 667 studies published between 2010 and 2024, selecting 175 relevant articles. The findings show that these technologies optimize critical processes such as Know Your Customer (KYC) and fraud prevention, though they face limitations in scalability, interoperability, and regulatory adaptation. This work provides a comprehensive perspective on their current and future impact in Fintech. Objective: Analyze the impact of AI and blockchain on Fintech platform security, evaluating benefits, limitations, and opportunities to improve critical processes and promote industry adoption. Method: This systematic literature review used five major academic databases: IEEE Xplore, ACM Digital Library, Taylor and Francis Online, Wiley Online Library, and Emerald Insight. From 667 studies, 175 met the inclusion criteria. Results: The integration of AI and blockchain significantly improves the security and efficiency of key processes such as KYC and fraud detection. However, barriers in scalability, interoperability, and regulation persist, limiting widespread implementation.
A insuficiência cardíaca (IC) constitui uma síndrome clínica complexa e progressiva, caracterizada por alterações estruturais e/ou funcionais do coração que comprometem sua capacidade de manter adequadamente o débito cardíaco e as pressões de enchimento. Sua fisiopatologia envolve a interação entre mecanismos neuro-hormonais, hemodinâmicos, inflamatórios, metabólicos e estruturais, com destaque para a ativação persistente do sistema nervoso simpático e do sistema renina-angiotensina-aldosterona, remodelamento ventricular, fibrose, estresse oxidativo, disfunção endotelial e alterações do metabolismo energético. O diagnóstico fundamenta-se na integração entre história clínica, exame físico, eletrocardiograma, radiografia de tórax, exames laboratoriais, biomarcadores como BNP e NT-proBNP e métodos de imagem, especialmente o ecocardiograma, que permite avaliar a função ventricular e classificar a doença conforme a fração de ejeção.
BACKGROUND:A substantial proportion of adults with major depressive disorder (MDD) exhibit an inadequate response to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) and experience persistent insomnia. Orexin receptor antagonists (ORAs) have emerged as a potential adjunctive treatment targeting hyperarousal mechanisms; however, their efficacy and safety remain uncertain. METHODS:A systematic search of PubMed (including MEDLINE), Web of Science, Cochrane CENTRAL, Scopus, Europe PMC, and CINAHL (via EBSCO), as well as ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP), was conducted from inception to August 2025. Randomized controlled trials (RCTs) evaluating adjunctive ORAs in adults with MDD and inadequate response to SSRIs/SNRIs were included. Outcomes included depressive severity (Montgomery-Åsberg Depression Rating Scale [MADRS], MADRS without sleep item [MADRS-WOSI], 17-item Hamilton Depression Rating Scale [HAMD17], Patient Health Questionnaire-9 [PHQ-9]), sleep disturbance (Patient-Reported Outcomes Measurement Information System-Sleep Disturbance [PROMIS-SD]), and safety (adverse events [AEs], serious adverse events [SAEs], and discontinuations). RESULTS:ORA therapy was associated with statistically significant improvements in depressive symptoms on MADRS (MD -1.96, 95% CI -3.29 to -0.63), MADRS-WOSI (MD -1.40, 95% CI -2.70 to -0.11), and PHQ-9 (MD -1.15, 95% CI -2.13 to -0.18), while no significant effect was observed for HAMD17. An exploratory pooled analysis combining MADRS and HAM-D17 suggested a small effect favoring ORA therapy; however, this finding should be interpreted with caution (SMD -0.15, 95% CI -0.27 to -0.03). Sleep improved on PROMIS-SD (MD -3.39, 95% CI -4.78 to -2.00). Safety outcomes did not differ significantly from placebo, and no drug-related deaths were reported. CONCLUSIONS:Adjunctive ORA therapy is associated with modest improvements in depressive symptoms and sleep disturbance, with no clear signal of increased adverse events; however, the available evidence is insufficient to establish comparative tolerability in SSRI/SNRI partial responders. These findings should be interpreted with caution given the limited number of studies. Larger, longer-duration, and more diverse RCTs are needed to define clinical relevance and long-term safety.
